A clinical manual on hypertension for primary care physicians.
Serves as an up-to-date reference on hypertension for use in clinical practice.
Includes dozens of clear and informative tables and figures to maximize comprehension.
Addresses the most recent and crucial developments in a very common chronic condition.
Gives a comprehensive review of currently available medications and combination therapy.
Approximately one billion people worldwide are affected by hypertension. About 24% of the adult population in the US are hypertensive, and the number is expected to increase with the rising rates of obesity and diabetes. As hypertension affects so many and spans across varying ages, genders, ethnicities, and socioeconomic classes, all clinicians are likely to encounter patients with hypertension on regular basis. Hypertension is one of the major causes of cardiovascular diseases, and timely diagnosis and treatment are essential.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends inantihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
Approximately one billion people worldwide are affected by hypertension. About 24% of the adult population in the US are hypertensive, and the number is expected to increase with the rising rates of obesity and diabetes. As hypertension affects so many and spans across varying ages, genders, ethnicities, and socioeconomic classes, all clinicians are likely to encounter patients with hypertension on regular basis. Hypertension is one of the major causes of cardiovascular diseases, and timely diagnosis and treatment are essential.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use thisclinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
Approximately one billion people worldwide are affected by hypertension. About 24% of the adult population in the US are hypertensive, and the number is expected to increase with the rising rates of obesity and diabetes. As hypertension affects so many and spans across varying ages, genders, ethnicities, and socioeconomic classes, all clinicians are likely to encounter patients with hypertension on regular basis. Hypertension is one of the major causes of cardiovascular diseases, and timely diagnosis and treatment areessential.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
The manual will give the reader a thorough overview of antihypertensive lifestyle modifications, first-line therapy, combination therapies, comorbid conditions, therapeutic challenges, and the latest trends in antihypertensive therapy.
Pharmaceutical companies can use this clinician’s manual as an excellent educational giveaway, as the booklet includes the latest clinical research results and treatment options for hypertension.
Innehållsförteckning
1 Definition of hypertension; 2 The J curve; 3 Drug therapy or lifestyle modification?; 4 First-line antihypertensive therapy: the simplistic viewpoint; 5 Hypertension as a gateway to cardiovascular risk modification; 6 To twofer or not to twofer; 7 When initial therapy is insufficient – To uptitrate, to substitute, or to combine?; 8 How aggressively should blood pressure be lowered?; 9 Evidence-based versus eminence-based therapy; 10 Combination therapy; 11 Comorbid conditions; 12 Therapeutic challenges; 13 Fashions and fads
Om författaren
Franz H Messerli, MD, FACC, FACP, is Director of the Hypertension Program, Division of Cardiology at St Luke’s-Roosevelt Hospital and Professor of Clinical Medicine at Columbia University, College of Physicians and Surgeons in New York City, NY, USA.
Dr Messerli received his MD degree from the University of Bern Medical School, Switzerland. He completed his internship and residency at the Department of Medicine, University Medical School in Bern, Switzerland. Dr Messerli completed a fellowship in cardiology at University Medical School in Bern, Switzerland, and carried out a hypertension cardiology research fellowship at the Clinical Research Institute in Montreal, Canada.
Dr Messerli is the author and co-author of more than 700 publications and book chapters. He has served on the Cardiorenal Advisory Committee of the US Food & Drug Administration (FDA) and Joint National Committee. He is a member of several editorial boards, and has received various awards and degrees for his scientific activity. He is also a Founding Member of the American Society of Hypertension; an Honorary Member of the Southern African Hypertension Society; and an Honorary Fellow or Member of the Philippine College of Physicians, the Brazilian Society of Cardiology, the Bulgarian Society of Cardiology, the Peruvian Society of Cardiology, and the Columbian Society of Cardiology.
Fler e-böcker från samma författare (r) / Redaktör
45 444 E-böcker i denna kategori
